ORBAS 20, 40 mg(Olmesartan Medoxomil INN)

Presented by

Mohammed Moshiur Rahaman

Senior Brand Executive

Brand Management Department

Strategic Brand Management Division

The ACME Laboratories Ltd.

ORBAS(Olmesartan Medoxomil INN 20, 40 mg)

Olmesartan effectively reduces blood pressure in adult patients along with 6 years old children

Price & Supply

Price: 20 mg (08 taka)

40 mg (15 taka)

Supply: 3x10 tablets

Product Group : A

IndicationFor the treatment of hypertension

Dosage & Administration 20 mg Once daily OR

may be increased after 2 weeks to 40 mg

Children (10 mg for weigh <35 kg & 20 mg for weigh >35 kg)

Endothelial Cell:The endothelium is the thin layer of cells that lines the interior surface of blood vessels and lymphatic vessels, forming an interface between circulating blood in the lumen and the rest of the vessel wall. The cells that form the endothelium are called endothelial cells.

Major function of Endothelial Cell:Vasoconstriction and vasodilation, and hence the control of blood pressure.

Dysfunction of Endothelial Cell:Endothelial dysfunction can result from and/or contribute to several disease processes, as occurs in hypertension, hypercholesterolemia, diabetes.

Product information of Losart, Valtin & Orbas

  Losart Valtin Orbas

Generic Losartan Valsartan Olmesartan

Dosage form Tablet Tablet Tablet

Strength 25, 50, 100 mg 80, 160 mg 20, 40 mg

Indication Hypertension, Congestive Heart failure

Hypertension, Heart failure, Myocardial infarction

Hypertension

AT1 affinity 10000 fold 20000 fold 12500 fold

tmax (h), on set of action

3-4 hrs 2 hrs 1.4-2.8 hrs

IMS market size

105 crore with 8% positive growth

9.7 crore with 6.21% negative growth

15.56 crore with 65% positive growth

Positioning Shows better control on blood pressure

Provides prompt & sustained blood pressure

More potent ARB Ensures double digit BP reduction

  Economic ARB Significantly reduces mortality and morbidity in patients with HF

Shows 24 hrs BP control, even final 4 hrs

  Also effective in CHF   Shows early onset of action compared to other ARBs

      Improves endothelial dependent coronary dilation in hypertensive patients

Mechanism of action

Blocks AT1 receptor, as a result Angiotensin II is unable to participate further reaction